Publicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (8)

2024

  1. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

    Haematologica

  2. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

2018

  1. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

    BMC Cancer, Vol. 18, Núm. 1

  2. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

    Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267

  3. Urine Metabolic Signatures of Multiple Environmental Pollutants in Pregnant Women: An Exposome Approach

    Environmental Science and Technology, Vol. 52, Núm. 22, pp. 13469-13480

2016

  1. 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S122